ALX Oncology Holdings Inc. (ALXO)
Automate Your Wheel Strategy on ALXO
With Tiblio's Option Bot, you can configure your own wheel strategy including ALXO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALXO
- Rev/Share 0.0
- Book/Share 1.6547
- PB 0.2778
- Debt/Equity 0.0197
- CurrentRatio 5.4707
- ROIC -1.314
- MktCap 24568207.0
- FreeCF/Share -2.0429
- PFCF -0.2254
- PE -0.1887
- Debt/Assets 0.0144
- DivYield 0
- ROE -1.0443
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ALXO | Jefferies | Hold | Buy | $2 | $3 | March 6, 2025 |
| Downgrade | ALXO | Jefferies | Buy | Hold | $12 | $2 | Dec. 19, 2024 |
News
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20 Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU® Data milestones expected …
Read More
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising anti-tumor activity
Read More
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company's investigational CD47-blocker evorpacept, when added to Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) with or without chemotherapy, did not meet the primary endpoints in the ASPEN-03 and ASPEN-04 trials of improved objective response rates (ORR) as compared to historical controls …
Read More
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.
Read More
ALX Oncology to Host Virtual R&D Day on March 5, 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m.
Read More
About ALX Oncology Holdings Inc. (ALXO)
- IPO Date 2020-07-17
- Website https://www.alxoncology.com
- Industry Biotechnology
- CEO Mr. Jason W. Lettmann
- Employees 65